Curasight to Restart Patient Enrolment in Early-stage Glioblastoma Study

MT Newswires · 2d ago
06:05 AM EDT, 10/05/2026 (MT Newswires) -- Curasight (CURAS.CO) will resume patient enrolment for the ongoing phase 1 clinical trial of uTREAT in glioblastoma after securing regulatory approval for the amended protocol. The Danish radiopharmaceutical company said Monday that the amended protocol covers treatment with uTREAT without mannitol-induced blood-brain barrier disruption. The study is designed to evaluate uTREAT's tumor delivery, biodistribution and dosimetry, alongside the identification of the "most efficient" delivery method. Topline data from the phase 1 study are expected in the first half of 2027.